32 Doses of bortezomib for desensitization is not well tolerated & is associated with only modest reductions in Anti-HLA antibody

Manuel A.Moreno Gonzales, Manish J. Gandhi, Carrie A. Schinstock, Natalie A. Moore, Byron H. Smith, Nong Y. Braaten, Mark D. Stegall

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Background.We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given.Methods. This study aimed to determine the safety and efficacy of 32 doses of BTZ (1.3 mg/m2 of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor. Results. Dose reduction was needed in 2 patients and 2 others completely discontinued therapy for adverse events. Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P < 0.01). No patient developed a negative crossmatch against their original intended donor, and the calculated panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged in all patients.Conclusions. These data suggest that 32 doses of BTZmonotherapy was not well tolerated and resulted in only a modest reduction in anti-HLA antibodies.

Original languageEnglish (US)
Pages (from-to)1222-1227
Number of pages6
JournalTransplantation
Volume101
Issue number6
DOIs
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of '32 Doses of bortezomib for desensitization is not well tolerated & is associated with only modest reductions in Anti-HLA antibody'. Together they form a unique fingerprint.

Cite this